References
- Fernandez MM, Coeytaux F, Ponce de León RG, Harrison DL. Assessing the global availability of misoprostol. Int J Gynaecol Obstet 2009;105:180–6.
- Faúndes A, Fiala C, Tang OS, Velasco A. Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy. Int J Gynaecol Obstet 2007;99(Suppl. 2):S172–7.
- Rouzi AA. Complications of self-induced medical abortion with misoprostol. Saudi Med J 2003;24:228.
- Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: Pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 2007;99(Suppl. 2):S160–7.
- Gonzalez CH, Marques-Dias MJ, Kim CA, et al Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998;351:1624–7.
- Philip NM, Shannon C, Winikoff B. Misoprostol and teratogenicity: Reviewing the evidence. InPhilip NM, Shannon C and Winikoff B, eds. The Robert H. Ebert program on critical issues in reproductive health. New York: The Population Council 2002; 1–20.
- Pollack AE, Pine RN. Opening a door to safe abortion: International perspectives on medical abortifacient use. J Am Med Womens Assoc 2000;55(3 Suppl.):186–8.
- Costa SH. Commercial availability of misoprostol and induced abortion in Brazil. Int J Gynaecol Obstet 1998;63(Suppl. 1):S131–9.
- World Health Organization. Safe abortion: Technical and policy guidance for health systems. Geneva: WHO 2003.